MTOR and acute myeloid leukemia: Our findings indicated that treatment with 0.5 μM VS‐5584 resulted in a significant reduction of p‐mTOR levels in AML cells, as well as a significant decrease in the phosphorylation levels of its direct downstream targets, S6 Kinase 1 (S6K1) and eukaryotic translation initiation factor 4E‐binding protein (4EBP).